Ionis Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
30/04/2025 14:32
Ionis Pharmaceuticals Inc IONS.OQ reported a quarterly adjusted loss of 93 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -98 cents. The mean expectation of twenty two analysts for the quarter was for a loss of $1.12 per share. Wall Street expected results to range from $-1.43 to -81 cents per share. Revenue rose 10.9% to $132.00 million from a year ago; analysts expected $125.32 million. Ionis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 93 cents. The company reported a quarterly loss of $147 million. Ionis Pharmaceuticals Inc shares had fallen by 1.2% this quarter and lost 14.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 0.4% in the last three months. In the last 30 days, four analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 8 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $60.00 This summary was machine generated from LSEG data April 30 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -1.12 | -0.93 | Beat |
| Dec. 31 2024 | -1.12 | -0.66 | Beat |
| Sep. 30 2024 | -1.16 | -0.95 | Beat |
| Jun. 30 2024 | -0.92 | -0.45 | Beat |
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors